Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collagen-induced arthritis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lim, Jung Yeon ^a   Im, Keon Il ^a   Lee, Eun Sol ^a   Kim, Nayoun ^a   Nam, Young Sun ^a   Jeon, Young Woo ^a   Cho, Seok Goo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IL10 PROTEIN, MOUSE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; STAT1 PROTEIN; STAT1 PROTEIN, MOUSE; TLR3 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 3;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; COCULTURE; COMPARATIVE STUDY; DBA MOUSE; ENZYME INDUCTION; EXPERIMENTAL ARTHRITIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOPHENOTYPING; IN VITRO STUDY; LYMPH NODE; LYMPHOCYTE ACTIVATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MOUSE; PATHOLOGY; PHYSIOLOGY; REGULATORY T LYMPHOCYTE; SPLEEN;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CD4-POSITIVE T-LYMPHOCYTES; COCULTURE TECHNIQUES; ENZYME INDUCTION; GENE EXPRESSION REGULATION; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; IN VITRO TECHNIQUES; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-BETA; INTERLEUKIN-10; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED DBA; SPLEEN; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 3;

EID: 84973294728     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26851     Document Type: Article

References (55)

1. Hu, Y. et al. Advances in research on animal models of rheumatoid arthritis. Clin Rheumatol 32, 161-165, doi: 10.1007/s10067-012-2041-1 (2013).
2. Benedetti, G. & Miossec, P. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol 44, 339-347, doi: 10.1002/eji.201344184 (2014).
3. Noack, M. & Miossec, P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 13, 668-677, doi: 10.1016/j.autrev.2013.12.004 (2014).
4. Lanas, A., Boers, M. & Nuevo, J. Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Ann Rheum Dis, doi: 10.1136/annrheumdis-2013-204155 (2013).
5. Colebatch, A. N., Marks, J. L. & Edwards, C. J. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev, CD008872, doi: 10.1002/14651858.CD008872.pub2 (2011).
6. Townsend, H. B. & Saag, K. G. Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks. Clin Exp Rheumatol 22, S77-82 (2004).
7. Nam, J. L. et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73, 516-528, doi: 10.1136/annrheumdis-2013-204577 (2014).
8. Aygun, D., Kaplan, S., Odaci, E., Onger, M. E. & Altunkaynak, M. E. Toxicity of non-steroidal anti-inflammatory drugs: a review of melatonin and diclofenac sodium association. Histo Histopathol 27, 417-436 (2012).
9. Ghannam, S., Bouffi, C., Djouad, F., Jorgensen, C. & Noel, D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther 1, 2, doi: 10.1186/scrt2 (2010).
10. Kim, N. & Cho, S. G. Clinical applications of mesenchymal stem cells. Korean J Intern Med 28, 387-402, doi: 10.3904/kjim.2013.28.4.387 (2013).
11. Kim, N. et al. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Ann Hematol 92, 1295-1308, doi: 10.1007/s00277-013-1796-z (2013).
12. Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579-1586, doi: 10.1016/S0140-6736(08)60690-X (2008).
13. Delarosa, O., Dalemans, W. & Lombardo, E. Toll-like receptors as modulators of mesenchymal stem cells. Front Immunol 3, 182, doi: 10.3389/fimmu.2012.00182 (2012).
14. Waterman, R. S., Tomchuck, S. L., Henkle, S. L. & Betancourt, A. M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLos One 5, e10088, doi: 10.1371/journal. pone.0010088 (2010).
15. Mao, F. et al. Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis. Inflamm Res 59, 219-225, doi: 10.1007/s00011-009-0090-y (2010).
16. Marinova-Mutafchieva, L., Gabay, C., Funa, K. & Williams, R. O. Remission of collagen-induced arthritis is associated with high levels of transforming growth factor-beta expression in the joint. Clin Exp Immunol 146, 287-293, doi: 10.1111/j.1365-2249.2006.03204.x (2006).
17. Djouad, F. et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 52, 1595-1603, doi: 10.1002/art.21012 (2005).
18. Park, M. J. et al. Transforming growth factor beta-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum 63, 1668-1680, doi: 10.1002/art.30326 (2011).
19. Asnagli, H. et al. Type 1 regulatory T cells specific for collagen-type II as an efficient cell-based therapy in arthritis. Arthritis Res Ther 16, R115, doi: 10.1186/ar4567 (2014).
20. Jonuleit, H. & Schmitt, E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 171, 6323-6327 (2003).
21. Vieira, P. L. et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 172, 5986-5993 (2004).
22. Saraiva, M. & O'Garra, A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 10, 170-181, doi: 10.1038/nri2711 (2010).
23. Engela, A. U., Baan, C. C., Dor, F. J., Weimar, W. & Hoogduijn, M. J. On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front Immunol 3, 126, doi: 10.3389/fimmu.2012.00126 (2012).
24. Wang, J., Han, W. G., Foks, A. C., Huizinga, T. W. & Toes, R. E. Neutralization of IL-4 reverses the nonresponsiveness of CD4+ T cells to regulatory T-cell induction in non-responder mouse strains. Mol Immunol 48, 137-146, doi: 10.1016/j.molimm.2010.08.017 (2010).
25. Hoogduijn, M. J. et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol 10, 1496-1500, doi: 10.1016/j.intimp.2010.06.019 (2010).
26. Polchert, D. et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38, 1745-1755, doi: 10.1002/eji.200738129 (2008).
27. Lee, J. et al. Interferon gamma suppresses collagen-induced arthritis by regulation of Th17 through the induction of indoleamine-2,3-deoxygenase. PLos One 8, e60900, doi: 10.1371/journal.pone.0060900 (2013).
28. Abumaree, M., Al Jumah, M., Pace, R. A. & Kalionis, B. Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev 8, 375-392, doi: 10.1007/s12015-011-9312-0 (2012).
29. Tatara, R. et al. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy 13, 686-694, doi: 10.3109/14653249.2010.542456 (2011).
30. Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4, 330-336, doi: 10.1038/ni904 (2003).
31. Lee, Y. K., Mukasa, R., Hatton, R. D. & Weaver, C. T. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 21, 274-280, doi: 10.1016/j.coi.2009.05.021 (2009).
32. Sun, Z. et al. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science 288, 2369-2373 (2000).
33. Dong, C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8, 337-348, doi: 10.1038/nri2295 (2008).
34. Ju, J. H. et al. Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells. Arthritis Rheum 64, 3543-3552, doi: 10.1002/art.34601 (2012).
35. Farina, C. et al. Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol 159, 12-19, doi: 10.1016/j.jneuroim.2004.09.009 (2005).
36. Barrat, F. J. et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195, 603-616 (2002).
37. Opitz, C. A. et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27, 909-919, doi: 10.1002/stem.7 (2009).
38. Ciorba, M. A. et al. Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol 184, 3907-3916, doi: 10.4049/jimmunol.0900291 (2010).
39. Finbloom, D. S. & Winestock, K. D. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol 155, 1079-1090 (1995).
40. Opitz, C. A. et al. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLos One 6, e19823, doi: 10.1371/journal.pone.0019823 (2011).
41. Marigo, I. & Dazzi, F. The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol 33, 593-602, doi: 10.1007/s00281-011-0267-7 (2011).
42. Schurgers, E., Kelchtermans, H., Mitera, T., Geboes, L. & Matthys, P. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 12, R31, doi: 10.1186/ar2939 (2010).
43. Chen, B. et al. Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6. Clin Exp Immunol 159, 292-302, doi: 10.1111/j.1365-2249.2009.04069.x (2010).
44. Lee, J. H. et al. The synergistic immunoregulatory effects of culture-expanded mesenchymal stromal cells and CD4(+)25(+)Foxp3+ regulatory T cells on skin allograft rejection. PLos One 8, e70968, doi: 10.1371/journal.pone.0070968 (2013).
45. Lim, J. Y. et al. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model. Cell Transplant 23, 703-714, doi: 10.3727/096368913X664577 (2014).
46. Im, K. I. et al. Induction of mixed chimerism using combinatory cell-based immune modulation with mesenchymal stem cells and regulatory T Cells for solid-Organ transplant tolerance. Stem Cells Dev, doi: 10.1089/scd.2013.0617 (2014).
47. van Hamburg, J. P. et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 63, 73-83, doi: 10.1002/art.30093 (2011).
48. Ma, S. et al. Immunobiology of mesenchymal stem cells. Cell Death Differ 21, 216-225, doi: 10.1038/cdd.2013.158 (2014).
49. Zhang, L., Yuan, S., Cheng, G. & Guo, B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. Plos One 6, e28432, doi: 10.1371/journal.pone.0028432 (2011).
50. Corre, B. et al. Type I interferon potentiates T-cell receptor mediated induction of IL-10-producing CD4(+) T cells. Eur J Immunol 43, 2730-2740, doi: 10.1002/eji.201242977 (2013).
51. Stewart, C. A. et al. Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J Clin Invest 123, 4859-4874, doi: 10.1172/JCI65180 (2013).
52. Soleimani, M. & Nadri, S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc 4, 102-106, doi: 10.1038/nprot.2008.221 (2009).
53. Kim, W. U. et al. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum 46, 1109-1120 (2002).
54. Brand, D. D., Latham, K. A. & Rosloniec, E. F. Collagen-induced arthritis. Nat Protoc 2, 1269-1275, doi: 10.1038/nprot.2007.173 (2007).
55. Camps, M. et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11, 936-943, doi: 10.1038/nm1284 (2005).